<PAGE>
================================================================================
SCHEDULE 14A INFORMATION
Proxy Statement Pursuant to Section 14(a) of the Securities
Exchange Act of 1934 (Amendment No. )
Filed by the Registrant [X]
Filed by a Party other than the Registrant [_]
Check the appropriate box:
[_] Preliminary Proxy Statement [_] Confidential, for Use of the
Commission Only (as Permitted by
Rule 14a-6(e)(2))
[X] Definitive Proxy Statement
[_] Definitive Additional Materials
[_] Soliciting Material Pursuant to Section 240.14a-11(c) or Section 240.14a-12
RESMED INC.
--------------------------------------------------------------------------------
(Name of Registrant as Specified In Its Charter)
N/A
--------------------------------------------------------------------------------
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
Payment of Filing Fee (Check the appropriate box):
[X] No fee required.
[_] Fee computed on table below per Exchange Act Rules 14a-6(i)(4) and 0-11.
(1) Title of each class of securities to which transaction applies:
-------------------------------------------------------------------------
(2) Aggregate number of securities to which transaction applies:
-------------------------------------------------------------------------
(3) Per unit price or other underlying value of transaction computed
pursuant to Exchange Act Rule 0-11 (Set forth the amount on which
the filing fee is calculated and state how it was determined):
-------------------------------------------------------------------------
(4) Proposed maximum aggregate value of transaction:
-------------------------------------------------------------------------
(5) Total fee paid:
-------------------------------------------------------------------------
[_] Fee paid previously with preliminary materials.
[_] Check box if any part of the fee is offset as provided by Exchange
Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee
was paid previously. Identify the previous filing by registration statement
number, or the Form or Schedule and the date of its filing.
(1) Amount Previously Paid:
-------------------------------------------------------------------------
(2) Form, Schedule or Registration Statement No.:
-------------------------------------------------------------------------
(3) Filing Party:
-------------------------------------------------------------------------
(4) Date Filed:
-------------------------------------------------------------------------
Notes:
<PAGE>
Dear Stockholder
You are cordially invited to attend the Annual Meeting of Stockholders of
ResMed Inc, at 3.00 pm local time, on Monday, November 6, 2000 at the Company's
premises, 14040 Danielson Street, Poway, California.
Information about the business of the meeting and the nominees for election
as directors of the Company are set forth in the Notice of Meeting and the
Proxy Statement, which are attached. This year you are asked to elect two
Directors of the Company, to amend the Certificate of Incorporation to double
the number of authorized shares of the Company's Common Stock from 50,000,000
to 100,000,000, and to ratify the selection of independent auditors for fiscal
year 2001.
Very truly yours
Peter C Farrell
Chairman and Chief Executive Officer
<PAGE>
RESMED INC
___________________________________________________
NOTICE OF ANNUAL MEETING OF STOCKHOLDERS
NOVEMBER 6, 2000
___________________________________________________
The Annual Meeting of Stockholders of ResMed Inc will be held at 14040 Danielson
Street, Poway, California on November 6, 2000, at 3.00 pm local time for the
following purposes:
1. To elect two directors, each to serve for a three year term;
2. To amend the Certificate of Incorporation to double the number of authorized
shares of the Company's common stock, par value of $0.004 per share, from
50,000,000 to 100,000,000 shares;
3. To ratify the selection of auditors to examine the consolidated financial
statements of the Company for the fiscal year ending June 30, 2001; and
4. To transact such other business as may properly come before the meeting.
Please refer to the accompanying Proxy Statement for a more complete description
of the matters to be considered at the meeting. Only stockholders of record at
the close of business on September 8, 2000 will be entitled to notice of, and to
vote at, the 2000 Annual Meeting and any adjournment thereof.
It is important that your shares be represented at the meeting. Even if you
plan to attend the meeting in person, please sign, date and return your proxy
form in the enclosed envelope as promptly as possible. This will not prevent
you from voting your shares in person if you attend, but will make sure that
your shares are represented in the event that you cannot attend.
Please sign, date and return the enclosed proxy promptly in the envelope
provided, which requires no United States postage.
By Order of the Board of Directors,
Walter Flicker
Secretary
Dated: September 15, 2000
<PAGE>
RESMED INC
_________________________
PROXY STATEMENT
_________________________
Annual Meeting of Stockholders to be held November 6, 2000
General
The enclosed proxy is solicited on behalf of the Board of Directors of ResMed
Inc (the "Company") for use at the 2000 Annual Meeting of Stockholders to be
held at 3.00 pm on Monday, November 6, 2000 at 14040 Danielson Street, Poway,
California (the "meeting") for the following purposes:
1. To elect two directors, to serve for a three year term;
2. To amend the Certificate of Incorporation of the Company to double the number
of authorized shares of the Company's Common Stock, par value of $0.004 per
share, from 50,000,000 to 100,000,000 shares;
3. To ratify the selection of auditors to examine the consolidated financial
statements of the Company for the fiscal year ending June 30, 2001; and
4. To transact such other business as may properly come before the meeting.
The enclosed proxy may be revoked at any time before its exercise by giving
written notice of revocation to the Secretary of the Company. The shares
represented by proxies in the form solicited by the Board of Directors received
by the Company prior to or at the Annual Meeting will be voted at the Annual
Meeting. If a choice is specified on the proxy with respect to a matter to be
voted upon, the shares represented by the proxy will be voted in accordance with
that specification. If no choice is specified, the shares will be voted as
stated below in this Proxy Statement.
It is expected that this Proxy Statement and the accompanying form of proxy will
first be mailed to stockholders of the Company on or about September 25, 2000.
The Company's Annual Report to Stockholders for Fiscal 2000 is enclosed with
this Proxy Statement along with a copy of the Company's Annual Report to the
Securities and Exchange Commission on Form 10K, but they do not form a part of
the proxy soliciting material. The cost of soliciting proxies will be borne by
the Company. Following the original mailing of the proxy soliciting material,
regular employees of the Company may solicit proxies by mail, telephone,
facsimile and personal interview. The Company may also request brokerage firms
and other nominees or fiduciaries to forward copies of the proxy soliciting
material and the 2000 Annual Report to beneficial owners of the stock held in
their names, and the Company will reimburse them for reasonable out-of-pocket
expenses incurred in doing so.
Voting Securities and Voting Rights
Holders of the Company's Common Stock of record as of the close of business on
September 8, 2000 (the "record date") are entitled to receive notice of and to
vote at the meeting. At the record date, the Company had outstanding 30,918,262
shares of Common Stock, the holders of which are entitled to one vote per share.
In order to constitute a quorum for the conduct of business at the Meeting, a
majority of the outstanding shares of the Company entitled to vote at the
Meeting must be represented at the Meeting. Shares represented by proxies that
reflect abstentions or "broker non-votes" (i.e., shares held by a broker or
nominee which are represented at the meeting, but with respect to which such
broker or nominee is not empowered to vote on a
<PAGE>
particular proposal) will be counted as shares represented at the meeting for
purposes of determining a quorum.
Common Stock Ownership of Principal Stockholders and Management
The following table shows the number of shares of Common Stock which, according
to information supplied to the Company, are beneficially owned as of the record
date by (i) each director of the Company (and director nominees), (ii) the Chief
Executive Officer, (iii) each of the Named Officers as defined on page 5, (iv)
each beneficial holder of more than five percent of the outstanding common stock
and (v) by all directors, nominees and executive officers of the Company as a
group. As used herein, "beneficial ownership" means the sole or shared power to
vote, or to direct the voting of, a security, or the sole or shared investment
power with respect to a security (i.e., the power to dispose of, or to direct
the disposition of, a security). A person is deemed, as of any date, to have
"beneficial ownership" of any security that the person has the right to acquire
within 60 days after that date.
-------------------------------------------------------------------------------
Amount and Nature of Percent of
Beneficial Ownership/(1)/ Class
Name of Beneficial Owner
-------------------------------------------------------------------------------
Commonwealth Bank of Australia 3,936,074/(2)/ 12.7%
Level 2, 48 Martin Place
Sydney NSW 2000 Australia
Deutsche Bank AG 2,636,875/(3)/ 8.5%
Taunusanlage 12, D-60325
Frankfurt am Main
Federal Republic of Germany
Principal Financial Group 2,398,101/(4)/ 7.8%
711 High Street
Des Moines IA 50392-0001
Peter C. Farrell 1,509,458/(5)/ 4.9%
c/o ResMed Inc
14040 Danielson Street
Poway CA 92064-6857
Christopher G Roberts 415,333/(6)/ 1.3%
Gary W Pace 206,333 0.7%
Michael A Quinn 110,497/(7)/ 0.4%
Donagh McCarthy 92,000/(8)/ 0.3%
Curt Kenyon 35,501/(9)/ 0.1%
Deirdre Stewart 29,321/(10)/ 0.1%
Walter Flicker 235,600/(11)/ 0.8%
All executive officers and
directors as a group (11 persons) 2,874,442/(12)/ 9.3%
-------------------------------------------------------------------------------
2
<PAGE>
(1) Except for the information based on Schedules 13G as indicated in the
footnotes hereto, beneficial ownership is stated as of September 8, 2000
and includes shares subject to options exercisable within 60 days after
September 8, 2000.
(2) Based on Schedule 13G filed by Commonwealth Bank of Australia. CBA has
shared dispositive power and shared voting power and beneficial ownership
over these shares.
(3) Based on Schedule 13G filed by Deutsche Bank AG, Deutsche Bank has shared
dispositive power and shared voting power and beneficial ownership over
these shares.
(4) Based on disclosure by Principal Financial Group, Principal has sole
dispositive and sole voting power and beneficial ownership over these
shares.
(5) Includes 114,298 shares of Common Stock which may be acquired upon the
exercise of options exercisable within 60 days after September 8, 2000.
(6) Includes 5,800 shares held by his wife, 314,200 shares held of record by
Cabbit Pty Ltd and 34,000 shares held by Acemed Pty Ltd, two Australian
corporations controlled by Dr. Roberts and his wife. Includes 61,333
shares of common stock which may be acquired upon the exercise of options
exercisable within 60 days after September 8, 2000.
(7) Includes 43,997 shares of common stock which may be acquired upon the
exercise of options exercisable within 60 days after September 8, 2000.
(8) Includes 74,000 shares of common stock which may be acquired upon the
exercise of options exercisable within 60 days after September 8, 2000.
(9) Includes 12,000 shares of common stock which may be acquired upon the
exercise of options exercisable within 60 days after September 8, 2000.
(10) Includes 15,334 shares of common stock which may be acquired upon the
exercise of options exercisable within 60 days after September 8, 2000.
(11) Includes 78,000 shares held by his wife, 80,000 shares held of record by
NewFolk Pty Ltd, an Australian corporation controlled by Mr. Flicker and
his wife and 10,000 shares held by each of his three children. Includes
47,600 shares of common stock which may be acquired upon the exercise of
options exercisable within 60 days after September 8, 2000.
(12) Includes, in addition to the shares described in notes 5 through 11 above,
121,067 shares of Common Stock which may be acquired upon the exercise of
options by the executive officers not named in the table.
The information presented is based upon the knowledge of management and, in the
case of the named individuals, upon information furnished by them.
Executive Officers
The executive officers of the Company, as at September 8, 2000 are:
<TABLE>
<CAPTION>
Name Age Position
<S> <C> <C>
Peter C Farrell 58 Chairman and Chief Executive Officer
Christopher G Roberts 46 Executive Vice President
Norman W DeWitt 50 General Counsel
Walter Flicker 45 Corporate Secretary
Adrian M Smith 36 Chief Financial Officer
Curt Kenyon 37 Vice President, US Sales and Marketing
Klaus Schindhelm 47 Vice President, Operations
Deirdre Stewart 44 Vice President, New Business and Clinical Education and Training
</TABLE>
For a description of the business background of Doctor Farrell and Doctor
Roberts, see "Matters to be Acted Upon/Election of Directors".
3
<PAGE>
Mr. DeWitt has been General Counsel since July, 1999. Mr. DeWitt was previously
Corporate Counsel (US) from October 1998 to June 1999, Vice President, US
Marketing from August 1997 to September 1998 and Vice President US Operations
from October 1994 to August 1997. From November 1990 to September 1994, he was
an attorney in private practice in Minneapolis, Minnesota, most recently
affiliated with the financial management advisory firm of Steven, Foster & Co.,
Inc. and as a consultant to the Company. Prior thereto, Mr. DeWitt held various
positions both as an attorney and executive for several companies based in
Minneapolis, MN. Mr. DeWitt holds a B.A. from Amherst College, a J.D. from the
University of Minnesota Law School and a L.L.M. from William Mitchell College of
Law.
Mr. Flicker has been Corporate Secretary since April, 1995. Mr. Flicker was
Vice President, US Operations from August 1997 to June 1999, Vice President,
Corporate Development from February 1995 to August 1997 and, from December 1989
until February 1995, he served as Vice President, Finance of the Company. He has
served as Corporate Secretary of the Company since August 1990. Prior thereto,
he was an engineering consultant with Bio-Agrix Pty Ltd, a biomedical
engineering consulting company and a Business Development Manager at Baxter
Center for Medical Research Pty Ltd, a subsidiary of Baxter International, Inc.
Mr. Flicker holds a B.E. with Honors in mechanical engineering and a Master's in
Biomedical Engineering from the University of New South Wales.
Mr. Kenyon has been Senior Vice President, Sales and Marketing for the US,
Canada and Latin America since 1999. From 1997 to 1999 he held the position of
Vice President, US Sales. Between 1995 and 1997 he was the Director of US Sales
and between 1994 and 1995 he held the position of Eastern Region Sales Manager.
Prior to his employment with ResMed, Mr. Kenyon was a Regional Sales Manager for
EMPI Inc and Medtronic both of Minneapolis MN. Mr. Kenyon holds a BA in Design
and Planning with a concentration in Business Administration from State
University of New York at Buffalo where he was a Cum Laude Graduate.
Dr. Schindhelm has been Vice President, Operations since January, 2000. Dr.
Schindhelm was Vice President, Product Development, from July 1998 to December
1999. From January 1995 to June 1998 Dr. Schindhelm was Professor and Head,
Graduate School of Biomedical Engineering, University of New South Wales and
from January 1990 to August 1994, Director, Centre for Biomedical Engineering,
University of New South Wales. Prior thereto, Dr. Schindhelm held various
academic positions in Biomedical Engineering at the University of New South
Wales. Dr. Schindhelm received a BE and a PhD in Chemical Engineering from the
University of New South Wales.
Mr. Smith has been Chief Financial Officer since February 1995. From January
1986 through January 1995, Mr. Smith was employed by Price Waterhouse
specializing in the auditing of listed public companies in the medical and
scientific field. Mr. Smith holds a Bachelor of Economics from Macquarie
University and is a Certified Chartered Accountant.
Dr. Stewart has been Vice President of Clinical Education and New Business since
early 2000. From 1999-2000 she held the position of Vice President of
Marketing and Education, and from 1997 to 1999 she was the Vice President of
Education and Training. From 1995-1997 Dr. Stewart worked as a nurse and
research scientist at the University of Sydney. She holds a BA from the
University of New South Wales and a PhD in sleep physiology from the University
of Sydney.
Executive Compensation
The following table sets forth certain information regarding the annual and
long-term compensation for services in all capacities to the Company for the
fiscal years ended June 30, 2000, 1999 and 1998 of those
4
<PAGE>
persons who were at June 30, 2000 (i) the chief executive officer of the
Company, (ii) one of the four other most highly compensated executive officers
of the Company whose annual salary and bonuses exceeded $100,000 or (iii) any
other executive officer who would have qualified under sections (i) or (ii) of
this paragraph but for the fact that the individual was not serving as an
executive officer of the registrant at the end of the 1999 fiscal year
(collectively, the "Named Officers").
Summary Compensation Table
<TABLE>
<CAPTION>
Annual Compensation Long Term Compensation Award Payouts
Name and Principal Position Year Salary ($) Bonus ($) Securities All Other
Underlying Options Compensation ($)/(1)/
-----------------------------------------------------------------------------------------------------------------------
<S> <C> <C> <C> <C> <C>
Peter C Farrell 2000 300,000 201,938 80,000 41,550
President and 1999 260,000 126,640 80,000 41,550
Chief Executive Officer 1998 214,500 138,483 30,000 31,658
Christopher G Roberts 2000 138,644 85,674 20,000 22,949
Executive Vice President 1999 129,150 52,234 16,000 17,922
1998 126,048 51,761 16,000 19,364
Curt Kenyon 2000 132,000 57,501 12,000 12,000
VP Sales and Marketing 1999 105,000 57,405 14,000 11,400
1998 95,000 66,173 12,000 9,852
Deirdre Stewart 2000 122,000 44,742 12,000 4,800
VP New Business and 1999 105,000 48,660 12,000 4,800
Clinical Education and Training 1998 85,000 31,924 10,000 -
Walter Flicker 2000 110,000 38,483 10,800 -
Corporate Secretary 1999 100,000 43,659 10,800 -
1998 84,473 27,308 14,000 7,103
-----------------------------------------------------------------------------------------------------------------------
</TABLE>
(1) These include pension plan payments and non-cash benefits.
Stock Options
<TABLE>
<CAPTION>
Option Grants in Last Fiscal Year
-----------------------------------------------------------------------------------------------------------------------
Individual Grants
Number of % of Total Exercise or Expiration Date Potential Realizable Value at
Securities Options Base Price Assumed Annual Rates of Stock
Underlying Granted to ($/Sh) Price Appreciation for Option
Options Employees in Term/(2)/
Name Granted/(1)/ Fiscal Year
5% 10%
--------------------------------------------------------------------------------------------------------------------
<S> <C> <C> <C> <C> <C> <C>
Peter C Farrell 80,000 6.0% $13.34375 July 30, 2009 $588,543 $1,449,609
Christopher G Roberts 20,000 1.5% $13.34375 July 30, 2009 147,136 362,402
Curt Kenyon 12,000 0.9% $13.34375 July 30, 2009 88,281 217,441
Deirdre Stewart 12,000 0.9% $13.34375 July 30, 2009 88,281 217,441
Walter Flicker 10,800 0.8% $13.34375 July 30, 2009 79,453 195,697
--------------------------------------------------------------------------------------------------------------------
</TABLE>
5
<PAGE>
(1) Options granted under the Company's 1997 Equity Participation Plan (the
"Plan") are exercisable starting 12 months after the grant date, with 33%
of the shares covered thereby becoming exercisable at that time and an
additional 33% of the option shares becoming exercisable on each successive
anniversary date, with all option shares exercisable beginning on the third
anniversary date. Under the terms of the Plan, this exercise schedule may
be accelerated in certain specific situations.
(2) Assumed annual rates of stock appreciation for illustrative purposes only.
Actual stock prices will vary from time to time based upon market factors
and the Company's financial performance. No assurance can be given that
such rates will be achieved.
The following table sets forth information concerning the stock option exercises
by the Chief Executive Officer and Named Officers during the fiscal year ended
June 30, 2000 and the unexercised stock options held at June 30, 2000 by the
named officers.
Aggregated Option Exercises in Last Fiscal Year and FY-End Option Values
<TABLE>
<CAPTION>
---------------------------------------------------------------------------------------------------------------------
Number of Securities Value of Unexercised In-the-
Shares Acquired Value Underlying Unexercised Money Options at FY- End
Name on Exercise Realized Options at FY- End
Exercisable Unexercisable Exercisable/(1)/ Unexercisable
---------------------------------------------------------------------------------------------------------------------
<S> <C> <C> <C> <C> <C> <C>
Peter C Farrell 26,808 $292,235 50,964 143,336 $1,127,953 $2,103,241
Christopher G Roberts - - 43,999 36,001 $ 954,280 $ 543,445
Curt Kenyon 13,334 $285,599 - 25,332 - $ 387,914
Deirdre Stewart 29,334 $293,160 4,000 23,334 $ 61,740 $ 353,536
Walter Flicker - - 35,733 22,667 $ 780,406 $ 352,760
---------------------------------------------------------------------------------------------------------------------
</TABLE>
(1) Represents the amount by which the closing sales price of the Company's
common stock on the New York Stock Exchange on June 30, 2000 ($26.75 per
share) multiplied by the number of shares to which the options apply
exceeded the aggregate exercise price of such options.
Report of the Compensation Committee
Introduction
Decisions regarding compensation of the Company's officers generally are made
based on recommendations by the Compensation Committee, which is composed of two
independent outside directors. The Compensation Committee decisions on
compensation of the Company's executive officers are reviewed and approved by
the full Board. Set forth below is a report submitted by Messrs Donagh McCarthy
and Michael A Quinn in their capacity as members of the Board's Compensation
Committee addressing the Company's compensation policies for fiscal year 2000 as
they affected executive officers of the Company, including the Chief Executive
Officer and the Named Officers.
General Philosophy
The Compensation Committee reviews and determines salaries, bonuses and all
other elements of the compensation packages offered to the executive officers of
the Company, including its Chief Executive Officer, and establishes the general
compensation policies of the Company.
The Company desires to attract, motivate and retain high quality employees who
will enable the Company to achieve its short and long term strategic goals and
values. The Company participates in a high-growth
6
<PAGE>
environment where substantial competition exists for skilled employees. The
ability of the Company to attract, motivate and retain high caliber individuals
is dependent in large part upon the compensation packages it offers.
The Company believes that its executive compensation programs should reflect the
Company's financial and operating performance. In addition, individual
contribution to the Company's success should be supported and rewarded.
The 1993 Omnibus Budget Reconciliation Act ("OBRA") became law in August 1993.
Under the law, income tax deductions of publicly-traded companies in tax years
beginning on or after January 1 1994 may be limited to the extent total
compensation (including base salary, annual bonus, stock option exercises, and
non-qualified benefits) for certain executive officers exceeds $1 million (less
the amount of any "excess parachute-payments" as defined in Section 280G of the
Code) in any one year. Under OBRA, the deduction limit does not apply to
payments which qualify as "performance-based". To qualify as "performance-
based," compensation payments must be based solely upon the achievement of
objective performance goals and made under a plan that is administered by a
committee of outside directors. In addition, the material terms of the plan
must be disclosed to and approved by shareholders, and the compensation
committee must certify that the performance goals were achieved before payments
can be made.
The Committee intends to design the Company's compensation programs to conform
with the OBRA legislation and related regulations so that total compensation
paid to any employee will not exceed $1 million in any one year, except for
compensation payments which qualify as "performance-based." The Company may,
however, pay compensation which is not deductible in limited circumstances when
sound management of the Company so requires.
The Company's executive and key employee compensation program consists of a base
salary component, a component providing the potential for an annual bonus based
on overall Company performance and a component providing the opportunity to earn
stock options linking the employee's long-term financial success to that of the
stockholders.
Compensation
Base Salary
Officers are compensated with salary ranges that are generally based on similar
positions in companies of comparable size and complexity to the Company. In
addition, the Company utilizes industry compensation surveys in determining
compensation. The primary level of compensation is based on a combination of
years of experience and performance. The salary of all officers is reviewed
annually in June with the amount of the increases (which take effect the
following July) based on factors such as Company performance, general economic
conditions, marketplace compensation trends and individual performance.
In fiscal year 2000, the Board approved salary increases for the named officers
as follows:
Peter C Farrell 15%
Christopher G Roberts 7%
Walter Flicker 10%
Curt Kenyon 26%
Deirdre Stewart 16%
7
<PAGE>
Bonus
The second compensation component is a bonus program under the Company's Bonus
Plan. Bonuses are primarily based on the Company's annual financial performance
and secondarily on the performance of the individual. Bonuses generally range
from zero to 60% of base salary. The measures of annual financial performance
used in determining the amount of bonuses include sales growth and cost control.
Stock Options
The third major component of the officer's compensation consists of stock
options. The primary purpose of granting stock options is to link the officers'
financial success to that of the stockholders of the Company. The exercise
price of stock options is determined by the Compensation Committee at the time
the option is granted, but generally may not be less than the prevailing market
price of the Company's Common Stock as of the date of grant. Options become
exercisable commencing a minimum of twelve months from the date of grant and are
exercisable for a maximum period of 10 years, as determined by the Compensation
Committee.
Stock options were issued to Officers of the Company during fiscal year 2000 in
accordance with the provisions of the Company's 1997 Equity Participation Plan.
CEO Compensation
The compensation of Dr. Farrell is based upon the performance of the Company and
the important role Dr. Farrell plays within the Company as its founder,
President and Chief Executive Officer, as a member of the Boards of the
Company's principal subsidiaries and as an active participant in new product and
corporate development.
Stock Option and Compensation Committee of the Company's Board of Directors:
Donagh McCarthy (Chairman)
Michael A Quinn
Dated: August 29, 2000
The above report of the Compensation Committee will not be deemed to be
incorporated by reference to any filing by the Company under the Securities Act
of 1933 or the Securities Exchange Act of 1934, except to the extent that the
Company specifically incorporates the same by reference.
Compensation Committee Interlocks and Insider Participation
The Compensation Committee of the Board of Directors is responsible for
executive compensation decisions as described above under "Board of Directors
and Committees of the Board". During fiscal year 2000, the committee consisted
of Mr. Donagh McCarthy (Chairman) and Mr. Michael A Quinn. Dr. Farrell did not
participate in discussions or decisions regarding his compensation package.
Performance Graph
Set forth below is a line graph comparing the cumulative stockholder return on
the Company's Common Stock against the cumulative total return of the S&P 500
Index and the Standard & Poors Medical Products and Supplies Index for the
period commencing June 2, 1995 (the date the Company's Common Stock commenced
trading on the NASDAQ Stock Market) through June 30, 2000, assuming an
investment of $100 on June 2, 1995.
8
<PAGE>
<TABLE>
<CAPTION>
June 2, June 30, June 30, June 30, June 30, June 30, June 30,
1995 1995 1996 1997 1998 1999 2000
----------------------------------------------------------------------------
<S> <C> <C> <C> <C> <C> <C> <C>
ResMed Inc. ............................ $100.00 $109.09 $140.91 $222.73 $414.21 $603.42 $972.73
S&P 500.................................. $100.00 $102.13 $125.73 $165.94 $212.57 $257.35 $272.70
S&Poors Medical Products and Supplies.... $100.00 $105.19 $136.63 $179.22 $237.75 $281.04 $303.47
</TABLE>
Section 16(a) Beneficial Ownership Reporting Compliance
Section 16(a) of the Securities Exchange Act of 1934 requires the Company's
directors and officers, and persons who own more than ten percent of a
registered class of the Company's equity securities, to file with the Securities
and Exchange Commission (the "Commission") and the National Association of
Securities Dealers National Market System initial reports of ownership and
reports of change in ownership of Common Stock and other equity securities of
the Company. Officers, directors and greater than ten-percent stockholders are
required by Commission regulation to furnish the Company with copies of all
Section 16(a) forms they file.
Based solely on its review of copies of such forms received by it with respect
to Fiscal 2000, or written representations from certain reporting persons, the
Company believes that during Fiscal 2000 all of its directors and executive
officers and persons who own more than 10% of the Company's Common Stock have
complied with the reporting requirements of Section 16(a) except that Dr.
Deirdre Stewart filed a correction to her Form 3 late and Curt Kenyon filed a
Form 5 in August, 2000 to substitute for Form 4's he failed to lodge during the
fiscal year.
Matters to Be Acted Upon
1. Election of Directors
---------------------
The Board of Directors, acting pursuant to the bylaws of the Company, has
determined that the number of directors constituting the full Board of
Directors shall be five at the present time.
11
<PAGE>
The Board is divided into three classes. One such class is elected every
year at the Annual Meeting of Stockholders for a term of three years. The
class of directors whose term expires in 2000 has two members, Peter C
Farrell, PhD and Gary W Pace, PhD. Accordingly, two directors are to be
elected at the 2000 Annual Meeting of Stockholders, who will hold office
until the 2003 Annual Meeting of Stockholders or until the director's prior
death, disability, resignation or removal.
The Board of Directors has nominated Peter C Farrell, PhD and Gary W Pace,
PhD for re-election as directors. Proxies are solicited in favor of these
nominees and will be voted for them unless otherwise specified. If Dr.
Farrell and Dr. Pace become unable or unwilling to serve as directors, it
is intended that the proxies will be voted for the election of such other
person, if any, as shall be designated by the Board of Directors.
Information concerning the nominees for director and the other directors
who will continue in office after the Annual Meeting is set forth below.
<TABLE>
<CAPTION>
Name Age Position with the Company
<S> <C> <C>
Peter C. Farrell(1) 58 President, Chief Executive Officer and
Chairman of the Board of Directors
Christopher G. Roberts(2) 46 Executive Vice President and Director
Donagh McCarthy(2)(4)(5) 53 Director
Gary W. Pace(1)(4) 52 Director
Michael A. Quinn(3)(4)(5) 53 Director
</TABLE>
(1) Term expires 2000
(2) Term expires 2002
(3) Term expires 2001
(4) Member of Audit Committee
(5) Member of Stock Option and Compensation Committee
Dr. Farrell has been President and a director of the Company since its
inception in June 1989 and Chief Executive Officer since July 1990. From
July 1984 to June 1989, Dr. Farrell served as Vice President, Research and
Development at various subsidiaries of Baxter International, Inc.
("Baxter") and from August 1985 to June 1989, he also served as Managing
Director of the Baxter Center for Medical Research Pty Ltd., a subsidiary
of Baxter. From January 1978 to December 1989, he was Foundation Director
of the Center for Biomedical Engineering at the University of New South
Wales where he currently serves as a Visiting Professor. He holds a B.E. in
chemical engineering with Honors from the University of Sydney, an S.M. in
chemical engineering from the Massachusetts Institute of Technology, a
Ph.D. in chemical engineering and bioengineering from the University of
Washington, Seattle and a D.Sc. from the University of New South Wales. Dr.
Farrell was named 1998 San Diego Entrepreneur of the Year for Health
Sciences.
Dr. Roberts joined the Company in August 1992 as Executive Vice President.
He has been director of the Company since September 1992. He also served as
a director of the Company from August 1989 to November 1990. From February
1989 to June 1992, Dr. Roberts served in various positions, most recently
as Vice President-Clinical and Regulatory Affairs, with medical device
subsidiaries of Pacific Dunlop Limited, a large multinational manufacturing
company. From January 1984 to December 1988, he served as President of BGS
Medical Corporation, a medical device company which was acquired in
September 1987 by Electro Biology Inc. ("EBI"), at which time he became
Vice President-Clinical and Regulatory Affairs of EBI. Dr. Roberts holds a
B.E. in chemical engineering with Honors from the University of New South
Wales, a M.B.A. from Macquarie University and a Ph.D. in biomedical
engineering from the University of New South Wales.
12
<PAGE>
Mr. McCarthy, a director of the Company since November 1994 has been a
consultant in the healthcare field since February 2000. From September
1996 to January 2000 he was President of RMS Inc, an affiliate of Baxter
Healthcare. From June 1993 until September 1996 he was the President of
the North America Renal Division of Baxter. Mr. McCarthy held various
positions at Baxter since 1982, including that of Vice President-Global
Marketing, Strategy and Product Development. Mr. McCarthy received a
bachelor's degree in engineering from the National University of Ireland
and a M.B.A. from the Wharton School, University of Pennsylvania.
Dr. Pace has been a director of the Company since July 1994. Dr. Pace is
President and Chief Executive Officer of RTP Pharma Corp. (formerly
Research Triangle Pharmaceutical Ltd), a biopharmaceutical company working
in the area of drug delivery, since January 1995. From January 1993 to
September 1994, he was the founding President and Chief Executive Officer
of Transcend Therapeutics Inc. (formerly Free Radical Sciences Inc.), a
biopharmaceutical company. From September 1989 to January 1993, he was
Senior Vice President of Clintec International, Inc., a Baxter/Nestle joint
venture and manufacturer of clinical nutritional products. Dr. Pace holds
a B.Sc. with Honors from the University of New South Wales and a Ph.D. from
the Massachusetts Institute of Technology.
Mr. Quinn, a director of the Company since September 1992, has been a
management and financial consultant since February 1992. From July 1988 to
January 1992, he served as Executive Chairman of Phoenix Scientific
Industries Limited, a manufacturer of health care and scientific products.
Mr. Quinn holds a B.Sc. in physics and applied mathematics and a B.Ec. from
the University of Western Australia and a M.B.A. from Harvard University.
Committees of the Board of Directors
The Board of Directors has two committees to assist in the management of
the affairs of the Company the Stock Option and Compensation Committee and
the Audit Committee. The Company does not have a standing Nominating
Committee.
Stock Option and Compensation Committee; Audit Committee
The Stock Option and Compensation Committee (the "Compensation Committee")
currently consists of Messrs Donagh McCarthy (Chairman) and Michael A
Quinn. The Compensation Committee administers the Company's 1995 Option
Plan and 1997 Equity Participation Plan and has the authority to grant
options under the latter plan. The Compensation Committee also makes
recommendations regarding the compensation payable, including compensation
under the Company's bonus plan, to the senior executive officers of the
Company.
The Audit Committee currently consists of Messrs Michael A Quinn
(Chairman), Donagh McCarthy and Gary Pace. This committee assists the Board
in fulfilling its functions relating to corporate accounting and reporting
practices and financial and accounting controls.
The Compensation Committee met twice and the Audit Committee met four times
during fiscal year 2000. These committees also met informally by telephone
during the fiscal year as the need arose. The Board of Directors held 4
meetings during fiscal year 2000.
Each director attended at least 75% of the aggregate of the total number of
meetings of the Board of Directors held during such period and the total
number of meetings held during such period by the committees of the Board
of Directors on which that director served.
13
<PAGE>
Each director, who is not an employee of the Company, received an annual
fee of $10,000 for his service as a director during fiscal 2000. In
addition, each director is reimbursed for his travel expenses for
attendance at all such meetings. Directors of the Company who are not
employees also hold and receive stock options under the Company's 1995
Option Plan and 1997 Equity Participation Plan.
Medical Advisory Committee
In addition the Company has an independent Medical Advisory Committee. The
Medical Advisory Committee comprises leading physicians in sleep medicine
who advise the board with respect to reviewing the Company's current and
proposed product lines from a medical perspective.
Vote
The Directors will be elected by a favorable vote of a plurality of the
shares of voting stock present and entitled to vote, in person or by proxy,
at the Meeting. Abstentions or broker non-votes as to the election of the
directors will not affect the election of the candidate receiving the
plurality of votes.
Unless instructed to the contrary, the shares represented by the proxies
will be voted FOR the election of the nominees named above as directors.
Although it is anticipated that the nominees will be able to serve as a
directors, should the nominees become unavailable to serve, the proxies
will be voted for such other person or persons as may be designated by the
Company's Board of Directors.
2. Approval of Amendment to Certificate of Incorporation To Effect a Doubling
--------------------------------------------------------------------------
of the Authorized Number of Shares of the Company's Common Stock, from 50
-------------------------------------------------------------------------
million to 100 million Shares
-----------------------------
On March 31, 2000 the Company effected a 2 for 1 stock split of the
outstanding shares of the Company's Common Stock, par value $0.004 per
share. The stock split had the effect of increasing the number of shares
on issue from approximately 15 million to approximately 30 million shares.
To reinstate the same number of the Company's authorized shares that
existed before the split, the Board of Directors is requesting approval of
an amendment to Article Fourth of the Company's Certificate of
Incorporation (the "Amendment") to double the number of authorized shares
of the Company's Common Stock, par value $0.004 per share, from 50 million
to 100 million shares.
The Board of Directors believes that the increase in the authorized number
of shares of the Company's Common Stock from 50 million to 100 million
shares is necessary to provide the Company with a sufficient number of
shares for any stock dividends or stock splits, financing, acquisitions,
management incentive or employee benefit plans and for other general
corporate purposes. No further action by stockholders would be necessary
prior to the issuance of additional shares of the Company's Common Stock
except as may be required by law or by the applicable regulations of the
New York Stock Exchange.
The existence of additional authorized shares of Common Stock could have
the effect of rendering more difficult or discouraging hostile takeover
attempts. The Company is not aware of any existing or planned effort on
the part of any party to accumulate material amounts of voting stock, or to
acquire the Company by means of a merger, tender offer, solicitation of
proxies in opposition to management or otherwise, or to change the
Company's management, nor is the Company aware of any person having made
any offer to acquire the voting stock or assets of the Company.
14
<PAGE>
The Board of Directors has no present plans for issuing any of the
additional shares of Common Stock which would be authorized by the
Amendment except as would be required in connection with Common Stock
presently reserved for issuance and under the Company's 1995 Stock Option
Plan and 1997 Equity Participation Plan.
The proposed additional shares of Common Stock would be a part of the
existing class of the company's Common Stock and, if and when issued, would
have the same rights and privileges as the shares of Common Stock presently
issued and outstanding.
The Amendment would become effective upon the filing with the Delaware
Secretary of State of a Certificate of Amendment to the Company's
Certificate of Incorporation. If the Amendment is approved by the required
vote of the Company's stockholders, the Company intends to file the
certificate of Amendment as soon as practicable after such approval is
obtained and expects that the filing would be made on or about November 7,
2000.
Amendment to the Certificate of Incorporation
If the Amendment is approved by the stockholders at the Annual Meeting of
Stockholders, Article Fourth of the Company's Certificate of Incorporation,
as amended, would read in full as follows:
"FOURTH: a) The Corporation shall be authorized to issue the following
shares of Capital Stock:
Class Number of Shares Par Value
----- ---------------- ---------
Common Stock 100,000,000 $0.004
Preferred Stock 2,000,000 $0.01
b) The designations and the powers, preferences and rights, and
the qualifications or restrictions thereof are as follows:
The Preferred Stock shall be issued from time to time in one or more
series, with such distinctive serial designations as shall be stated and
expressed in the resolution or resolutions providing for the issue of such
shares from time to time adopted by the Board of Directors; and in such
resolution or resolutions providing for the issuance of shares of each
particular series, the Board of Directors is expressly authorized to fix
the annual rate or rates of the dividends for the particular series; the
dividend payment dates for the particular series and the date from which
dividends on all shares of such series issued prior to the record sate for
the first dividend payment shall be cumulative; the redemption price or
prices for the particular series; the voting powers for the particular
series; the rights, if any, of the holders of the shares of the particular
series to convert the same into share of any other series or class or other
securities of the corporation, with any provisions for the subsequent
adjustment of such conversion rights; and to classify or reclassify any
unissued shares by fixing or altering from time to time any of the
foregoing rights, privileges and qualifications.
All shares of Preferred Stock of any one series shall be identical with
each other in all respects, except that shares of any one series issued at
different times may differ as to the dates from which dividends thereon
shall be cumulative; and all Preferred Stock shall be of equal rank,
regardless of series, and shall be identical in all respects except as to
the particulars fixed by the Board as hereinabove provided or as fixed
herein."
15
<PAGE>
Required Vote
The affirmative vote of a majority of the Company's outstanding shares of
Common Stock present or represented and entitled to vote at the 2000 Annual
Meeting of Stockholders is required to approve the Amendment to the
Certificate of Incorporation effecting the increase in the number of
authorized shares. Abstentions as to this Proposal 2 will be treated as
votes against the Amendment to the Certificate. Broker non-votes, however,
will be treated as unvoted for purposes of determining approval of Proposal
2, and thus will not be counted as votes for or against the Amendment to
the Certificate. Unless instructed to the contrary, properly executed
Proxies will be voted FOR Proposal 2. Your Board of Directors recommends a
vote FOR approval of the Amendment to increase the authorized number of
shares of Common Stock.
3. Ratification of Selection of Auditors
-------------------------------------
The Board of Directors, following the recommendation of the Audit
Committee, has selected the independent public accounting firm of KPMG LLP
as the auditors to examine the consolidated financial statements of the
Company for fiscal year 2001. The proxies solicited on behalf of the Board
of Directors will be voted to ratify selection of that firm unless
otherwise specified.
KPMG LLP has served as the independent auditors for the Company since 1994.
Representatives of KPMG LLP are expected to be present at the Annual
Meeting of Stockholders. They will have the opportunity to make statements
if they desire to do so and will be available to respond to appropriate
questions.
4. Other Business
--------------
The Board of Directors does not know of any other business to be presented
to the Annual Meeting of Stockholders. If any other matters properly come
before the meeting, however, the persons named in the enclosed form of
proxy will vote the proxy in accordance with their best judgment.
Stockholder Proposals for 2001 Annual Meeting
The Company expects to hold the 2001 Annual Meeting of Stockholders on November
6, 2001. If a stockholder wishes to present a proposal at the 2001 Annual
Meeting of Stockholders, the proposal must be received by the Secretary of the
Company on or before May 18, 2001 to be considered for inclusion in the
Company's Proxy Statement and form of proxy relating to the 2001 Annual Meeting
of Stockholders. Pursuant to these new rules, if the Company has not received
notice on or before August 18, 2001 of any matter a stockholder intends to
propose for a vote at the 2000 Annual Meeting of Stockholders, then a proxy
solicited by the Board of Directors may be voted on such matter in the
discretion of the proxy holder, without discussion of the matter in the proxy
statement soliciting such proxy and without such matter appearing as a separate
item on the proxy card.
By Order of the Board of Directors
Walter Flicker
Secretary
Dated: September 15, 2000
16
